Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10584MR)

This product GTTS-WQ10584MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Solid tumors, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ10584MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11816MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ6694MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ4457MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ2528MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ5595MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP7766
GTTS-WQ14513MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ3641MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ11683MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MHAB5553A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW